Sammamish, Washington--(Newsfile Corp. - August 7, 2025) - TempraMed Ltd. ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is proud to announce a new partnership with the Diabetes Education & Camping Association (DECA) by providing VIVI Cap devices to diabetes camps across the United States. As part of this partnership, TempraMed is providing these critical temperature-sensitive storage devices to support children and teens living with type 1 diabetes, ensuring their insulin remains safe and effective during camp activities, regardless of weather or outdoor conditions.
The VIVI Cap, a reusable, power-free temperature shield for insulin pens, is designed to protect insulin from extreme heat or cold-making it an ideal solution for active campers spending extended time outdoors. This partnership aligns with TempraMed's mission to empower people with diabetes to live full, spontaneous lives without compromising their health or safety.
"Diabetes camp is a powerful experience that helps children build skills to manage their condition, gain confidence and independence, and find social support that lasts a lifetime," said Lisa Gier, Executive Director of DECA. "Through this new partnership, all DECA member camps will now have access to TempraMed's VIVI Cap devices. We are thrilled to welcome TempraMed to the diabetes camping community and are grateful for their support."
"We are honored to partner with DECA and contribute to the safety and wellbeing of children at diabetes camps this summer," said Ron Nagar, CEO of TempraMed. "At TempraMed, we believe that diabetes should never get in the way of living fully-and that includes summer camp. With the VIVI Cap, campers, caregivers, and staff can feel confident that insulin is protected throughout the day."
Through this partnership, tens of thousands of children attending DECA-affiliated camps will have access to VIVI Cap devices, helping reduce the risk of insulin degradation due to environmental exposure. The initiative also raises awareness about the importance of temperature protection in maintaining insulin efficacy, particularly in high-temperature settings where refrigeration or controlled storage may not be readily available.
About DECA
The Diabetes Education & Camping Association (DECA) strengthens the global diabetes camp community through connection, education and innovation. Your local diabetes camp would love to connect with you! Find your local camp here: https://www.diabetescamps.org/all-camp-details.
About TempraMed
TempraMed is a leading medical device technology company transforming medication management for individuals with chronic conditions. TempraMed has developed patented, FDA-registered, space-grade thermal insulation devices that work 24/7 without batteries or external power. With a proven product line including VIVI Cap and VIVI Epi, and a smart technology platform on the horizon, TempraMed enables patients and healthcare providers to confidently manage temperature-sensitive medications anywhere, anytime. TempraMed ensures medication potency, enables precise tracking, and facilitates information sharing between patients, caregivers, and healthcare providers. Committed to improving patient outcomes, TempraMed bridges the gap between medical device engineering and digital health innovation. The company provides intuitive solutions that help patients with chronic conditions live more confidently. For more information, visit www.tempramed.com.
Media Contact:
Brenda Zeitlin
Vice President, Marketing
Brenda@tempramed.com
Investor Contact:
Julia Becker
Vice President, Capital Markets
T: +1 (604) 785-0850
E: julia@tempramed.com
Cautionary Statements
This press release contains "forward-looking statements or information". Forward-looking statements can be identified by words such as: anticipate, intend, plan, goal, seek, believe, project, estimate, expect, strategy, future, likely, may, should, will and similar references to future periods. Examples of forward-looking statements in this press release include statements made regarding information about future plans, expectations and objectives of the Company overall.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The Company may not actually achieve its plans, projections, or expectations. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the adequacy of our cash flow and earnings, the availability of future financing and/or credit, developments and changes in laws and regulations, consumer sentiment towards the Company's products, failure of counterparties to perform their contractual obligations, government regulations, competition, loss of key employees and consultants, and general economic, market or business conditions, the impact of technology and social changes on the products and industry.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable securities laws, we undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/261237
SOURCE: TempraMed
